Novartis and DSM trim jobs


Pharmaceutical firm Novartis and nutritional products specialist DSM are both set to cut jobs in Switzerland. Novartis’s will lose around 500 support and operational roles, while DSM aims to cut 120 staff. Novartis also plans to close a manufacturing plant in the US, affecting 525 employees.

Novartis says that the loss of patent exclusivity on blood pressure drug Diovan (valsartan) has reduced demand for products produced at the Suffern, New York, site. Following its phased closure over 2–3 years, the buildings will be demolished and equipment transferred elsewhere or sold, although company spokeswoman Julie Masow adds that the company is open to other proposals for the site.

Novartis adds that its planned product launches for 2014 will be accompanied by ‘several hundred’ new jobs in Switzerland, for example in supply chain management for its Sandoz generics arm and manufacturing for over-the-counter products.

DSM’s cuts are the fallout of reorganisation after recent acquisitions. The affected positions will come from both central support and R&D areas.


Related Content

Job cuts at Lundbeck and DSM

27 August 2015 Business

news image

Each cutting around 1000 roles in reorganisation efforts

Novartis to shut Horsham site

6 November 2013 Business

news image

UK research centre closure to result in the loss of 371 jobs as firm consolidates its global R&D base

Most Commented

New German excellence strategy gets political go-ahead

21 June 2016 News and Analysis

news image

Scheme will provide €500 million to bolster country’s best universities and fund best research

Mass spec backpack for chemical analysis on the go

4 March 2014 Research

news image

Portable analyser can detect explosives, chemical weapons and drug out in the field